Dimensional Fund Advisors’s Vaxcyte PCVX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$69.4M Buy
1,194,754
+818,982
+218% +$44.5M 0.01% 1412
2026
Q1
$21.8M Buy
375,772
+183,986
+96% +$9.99M ﹤0.01% 1924
2025
Q4
$8.85M Buy
191,786
+163,419
+576% +$7.31M ﹤0.01% 2325
2025
Q3
$1.02M Sell
28,367
-81,513
-74% -$2.7M ﹤0.01% 2891
2025
Q2
$3.57M Sell
109,880
-117,551
-52% -$3.85M ﹤0.01% 2613
2025
Q1
$8.74M Sell
227,431
-66,275
-23% -$5.3M ﹤0.01% 2311
2024
Q4
$24M Buy
293,706
+157,277
+115% +$15.6M 0.01% 1918
2024
Q3
$15.6M Buy
136,429
+100,787
+283% +$9.08M ﹤0.01% 2110
2024
Q2
$2.69M Sell
35,642
-11,869
-25% -$808K ﹤0.01% 2681
2024
Q1
$3.25M Buy
47,511
+13,068
+38% +$905K ﹤0.01% 2666
2023
Q4
$2.16M Sell
34,443
-6,276
-15% -$326K ﹤0.01% 2772
2023
Q3
$2.08M Buy
40,719
+30,157
+286% +$1.49M ﹤0.01% 2772
2023
Q2
$527K Sell
10,562
-267,481
-96% -$12.7M ﹤0.01% 3054
2023
Q1
$10.4M Buy
+278,043
New +$11.8M ﹤0.01% 2215
2022
Q3
$5.94M Buy
247,329
+169,807
+219% +$4.3M ﹤0.01% 2369
2022
Q2
$1.69M Buy
+77,522
New +$1.79M ﹤0.01% 2792

Other funds holding PCVX

Dimensional Fund Advisors's PCVX Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Vaxcyte (PCVX) stake by 218% in Q2 2026, buying an estimated $44.5M and bringing the position to 1,194,754 shares worth $69.4M. The position accounts for 0.01% of the portfolio, ranked #1412.

Dimensional Fund Advisors first reported a position in PCVX in Q2 2022 and has held it in 16 quarters since. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Dimensional Fund Advisors held 1,194,754 shares of Vaxcyte worth $69.4M as of Q2 2026.
  • Dimensional Fund Advisors bought 818,982 Vaxcyte shares in Q2 2026, an estimated $44.5M.
  • Vaxcyte made up 0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #1412 holding.
  • Dimensional Fund Advisors first reported a position in Vaxcyte in Q2 2022 and has held it in 16 quarters since.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.